Incyte Corporation (INCY) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Wilmington, DE, United States. The current CEO is William J. Meury.
INCY has IPO date of 1993-11-04, 2,617 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $19.44B.
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes innovative therapies for oncology and inflammatory diseases in the United States and internationally. The company's commercial portfolio includes JAKAFI for myelofibrosis and polycythemia vera, PEMAZYRE for fibroblast growth factor receptor-driven cancers, and ICLUSIG for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Its pipeline comprises multiple clinical-stage candidates, including ruxolitinib for steroid-refractory chronic graft-versus-host disease, pemigatinib for various solid tumors, and Retifanlimab for MSI-high cancers and non-small cell lung cancer. The company maintains strategic partnerships with major pharmaceutical firms including Novartis, Eli Lilly, and others to accelerate development of combination therapies and novel treatment approaches. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte focuses on addressing significant unmet medical needs in oncology and immunology.
